GLP-1s Show No Causal Link To Suicidal Thoughts, Actions In Preliminary FDA Review; Sentinel Scan Is Next

 
• By Sue Sutter

US FDA will share final conclusions about safety of the class, which carries indications for type 2 diabetes and weight management, after conducting a meta-analysis of clinical studies across all GLP-1 receptor agonist products and a postmarketing data analysis in the Sentinel system.

Thumbs up
FDA's investigation into GLP-1s and suicidal thoughts has resulted in a tentative thumbs up for the drug class, with more assessments to come. • Source: Shutterstock

More from Drug Safety

More from Pink Sheet